Video Experimental Relacionado

Updated: Jan 13, 2026

03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.3K

Rituximab e Inmunoglobulina Intravenosa (IVIG) para la Fascitis Eosinofílica Refractaria: Un Reporte de Caso

Maryam Sahebari¹, Motahhareh Karimoddini², Naser Tayyebi Meibodi³

¹Rheumatic Diseases Research Center, Mashhad University of Medical Sciences Mashhad Iran.

Clinical case reports

|January 7, 2026

Abstract:

Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40-year-old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long-term safety for EF.

Palabras clave:

fascitis eosinofílica inmunoglobulina intravenosa fascitis eosinofílica refractaria rituximab

Videos de Conceptos Relacionados

01:14

Myocarditis III: Medical Management

168

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

168